Skip to main content
. 2024 Feb 29;18(10):7618–7632. doi: 10.1021/acsnano.4c00550

Figure 7.

Figure 7

Therapeutic benefits of AnCHNPs when used in combination with RT, tested in both B16F10 and MB49 tumor bearing C57BL/6 mice. (a–d) Therapy study with the B16F10 model. (a) Scheme of the experiment. On Day 0 and Day 2, animals received radiation (10 Gy) applied to tumors, followed by i.t. administration of 200 μg/kg AnCHNPs (RT+AnCHNPs; n = 5). PBS alone (PBS), PBS plus RT (RT+PBS), and AnCHNPs alone (AnCHNPs) were also tested (n = 5). Moreover, anti-CD4 or anti-CD8 antibodies (10 mg/kg, injected i.p. on Day 0 and Day 4) were administered in addition to the RT-AnCHNPs combination (RT+AnCHNPs+αCD4 and RT+AnCHNPs+αCD8, respectively; n = 5). (b) Average tumor growth, animal survival, and body weight curves. (c) Individual tumor growth curves. (d) Post-mortem H&E and Ki67 staining of tumor tissues taken from different treatment groups. Scale bars, 200 μm. (e–g) Therapy study with the MB49 model. (e) Scheme of the MB49 experiment. On Day 0 and Day 2, animals received radiation (10 Gy) applied to tumors, followed by i.t. administration of AnCHNPs (200 μg/kg) (RT+AnCHNPs; n = 5). PBS alone (PBS) and PBS plus RT (RT+PBS) were also tested (n = 5). (f) Average tumor growth, animal survival, and body weight curves. (g) Individual tumor growth curves. Data are presented as the mean ± s.d. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.